Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin
Main finding · MACLEResult — go to the resultHazard ratio 0.70 95 % CI 0.66–0.76Authors' conclusion
Tirzepatide was associated with a significantly lower risk of cardiovascular and limb events compared to sitagliptin in patients with T2D.
Study context
- Population
- Patients with T2D who initiated tirzepatide or sitagliptin between January 2022 and December 2023matched cohort
- Participants
- 31,751 vs 31,751
- Exposure
- Tirzepatide vs sitagliptin
- Tirzepatiden = 31,751
- Sitagliptinn = 31,751reference
- Outcome
- Major adverse cardiovascular and limb events (MACLE): composite of MACE (all-cause death, MI, stroke) and MALE (all-cause death, major lower extremity amputation)
- Follow-up
- 1 year
Methodological detailspropensity score matching, TriNetX global health research network
- Propensity score matching
- TriNetX global health research network
Main finding
MACLE
Hazard ratio
0.70
95 % CI 0.66–0.76
P < 0.001
By group
Tirzepatidevs Sitagliptin
HR 0.70 (95 % CI 0.66–0.76); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95 % CI) | |
|---|---|---|
| MACE | 0.71 (0.66–0.76) | |
| MALE | 0.39 (0.34–0.46) | |
| Major lower extremity amputation | 0.61 (0.44–0.84) | |
| 0.20.5125Hazard ratio (log scale) |
Subgroups
- Consistent benefits were observed across major subgroups
Original publication
Major adverse cardiovascular and limb events caused by tirzepatide in patients with type 2 diabetes at high cardiovascular risk: A comparison with sitagliptin. Diabetes Res Clin Pract. Published 23 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →